KURA
HealthcareKura Oncology, Inc.
$9.54
$-0.80 (-7.69%)
Jan 5, 2026
Price History (1Y)
Analysis
Kura Oncology, Inc. is a healthcare company operating in the biotechnology industry. With a market capitalization of $830.15 million and revenue of $104.03 million (TTM), the company has a significant presence in the sector. It employs 192 individuals. Financially, Kura Oncology has faced losses, with net income totaling -$216,884,000 (TTM) and EBITDA standing at -$238,984,992. The company's cash balance is substantial at $549.67 million, while its debt stands at $19.47 million. This results in a debt-to-equity ratio of 8.03. Profit margins are negative across the board: gross margin (-115.6%), operating margin (-385.5%), and profit margin (-208.5%). Returns on equity (-65.1%) and assets (-26.6%) also reflect significant financial strain. Valuation metrics paint a mixed picture, with a forward P/E ratio of -4.00 and an EV/EBITDA ratio of -1.54. The price-to-book ratio is 3.42, while the price-to-sales ratio stands at 7.98. These figures indicate a complex valuation context for Kura Oncology.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Kura Oncology, Inc.
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $830.15M
- P/E Ratio
- N/A
- 52-Week High
- $12.49
- 52-Week Low
- $5.41
- Avg Volume
- 1.90M
- Beta
- 0.25
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 192